The U.S. Food and Drug Administration (FDA) has cleared Find Therapeutics Inc.’s Investigational New Drug (IND) application for FTX-101, enabling the biopharmaceutical company to initiate its planned Phase 1 clinical study of FTX-101 in healthy volunteers.   FTX-101, find’s lead compound, is a first-in-class remyelinating agent that aims to restore vision in people suffering from Chronic Optic Neuropathy (CON).   “The FDA’s clearance of our IND marks an important achievemen...